CPHI Europe 2026: Pharmaceutical Opportunities in Central Asia

Central Asia offers strategic opportunities for the European pharmaceutical industry. Turning this potential into tangible business requires market expertise, reliable partners and a commercial strategy tailored to local conditions.

With this objective, the President of ACIR Southern Europe and the Milan project office team actively participated in CPHI Worldwide 2026 (CPHI Europe), one of the pharmaceutical industry’s leading international gatherings.

International dialogue and new partnerships

During the event, ACIR specialists reconnected with established partners and colleagues while holding dozens of meetings with European and international companies interested in exploring Central Asian markets.

The President’s participation in thematic sessions was particularly valuable. He shared practical insights into operating in a region with significant growth prospects, discussing favourable market conditions, cooperation opportunities and the importance of understanding the specific business environment in each country.

An ecosystem supporting European exports

ACIR offers European companies more than a route to market. Its business ecosystem brings together potential local partners, professionals who live and work across the region, and practical knowledge that helps companies make informed decisions.

This support is complemented by private and institutional export instruments that help businesses develop competitive commercial proposals aligned with local market needs.

Turning meetings into projects

ACIR’s project office has already launched a second round of negotiations with interested companies. Upcoming meetings will focus on defining cooperation terms and establishing concrete areas for collaboration.

ACIR Southern Europe continues to act as a strategic bridge between Europe and Central Asia, helping turn international interest into sustainable commercial opportunities for European manufacturers and their regional partners.